Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 5/2011

01-10-2011 | Editorial

Pharmaceutical patents, R&D incentives and access to new drugs: new ways of progress at the crossroad

Authors: Fernando Antoñanzas, Carmelo Juárez-Castelló, Roberto Rodríguez-Ibeas

Published in: The European Journal of Health Economics | Issue 5/2011

Login to get access

Excerpt

Patents are defined as a right granted to innovators by governments for the exclusive production and marketing of an innovation for a limited period of time. Patent owners enjoy a legal monopoly. Patents rights have traditionally been considered a good mechanism to provide incentives to innovate as it allows innovators to obtain monopolistic benefits that compensate the R&D expenditures. In the case of the pharmaceutical industry, as imitation of new drugs is relatively easy and it is difficult to keep the ‘first mover’ advantage in the market, it seems that the patent system is the only mechanism to incentive the innovative activity. …
Literature
1.
Angell, M.: The truth about the drug companies. How they deceive us and what to do about it. Random House, New York (2004)
2.
Commission on Intellectual Property Rights, Innovation and Public Health: Public health, innovation and intellectual property rights. World Health Organization, Geneva (2006). Available at www.​who.​int
3.
Correa, C.: Guidelines for the examination of pharmaceutical patents: developing a public health perspective—a working paper. ICTSD, WHO, UNCTAD (2006)
4.
DiMasi, J.A., Grabowski, H.G.: Should the patent system for new medicines be abolished? Clin. Pharmacol. Ther. 82(5), 488–490 (2007)PubMedCrossRef
5.
Danzon, P.M., Towse, A.: Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int. J. Health Care Finance Econ. 3, 183–205 (2003)PubMedCrossRef
6.
Gagnon, M.A., Lexchin, J.: The cost of pushing bills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 5(1), 29–33 (2008)CrossRef
7.
Grabowski, H.G., Wang, Y.R.: The quantity and quality of worldwide new drug introductions, 1982–2003. Health Aff. 25(2), 452–460 (2006)CrossRef
8.
Hong, S.H., Shepherd, M.D., Scoones, D., Wan, T.: Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. J. Manag. Care Pharm. 11(9), 746–754 (2005)PubMed
9.
Kremer, M., Glennerster, R.: Strong medicine: creating incentives for pharmaceutical research on neglected diseases. Princeton University Press, Princeton (2004)
10.
11.
Ridley, D., Grabowski, H., Moe, J.: Developing drugs for developing countries. Health Aff. 25(2), 313–324 (2006)CrossRef
12.
Stiglitz, J.E.: Making globalization work. WW Norton, New York (2006)
13.
14.
Metadata
Title
Pharmaceutical patents, R&D incentives and access to new drugs: new ways of progress at the crossroad
Authors
Fernando Antoñanzas
Carmelo Juárez-Castelló
Roberto Rodríguez-Ibeas
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 5/2011
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-011-0336-9

Other articles of this Issue 5/2011

The European Journal of Health Economics 5/2011 Go to the issue

Original paper

Atrial fibrillation: the cost of illness in Sweden

Original Paper

Discrimination in waiting times by insurance type and financial soundness of German acute care hospitals

Original Paper

Cost of low back pain in Switzerland in 2005

Original Paper

Comparing top-down and bottom-up costing approaches for economic evaluation within social welfare

Original Paper

Ageing and health care expenditure in EU-15

Original Paper

Hospital’s activity-based financing system and manager: physician interaction